Core Insights - Huatai Securities reported that Connoa disclosed Phase I clinical results for TSLP/IL-13 dual antibody CM512 for treating AD on November 4, showing promising efficacy and potential for longer dosing cycles [1] Group 1: Clinical Results - After three doses in the first month, the 300mg dose group achieved EAS-75 and EAS-90 rates of 58.3% and 41.7% respectively over 12 weeks, outperforming the placebo group which had rates of 21.4% and 0% [1] - CM512 demonstrated a long half-life of 70 days, indicating potential for extended dosing intervals [1] Group 2: Market Position and Financial Projections - The report suggests that CM512 has shown sufficient drug-like properties and competitive potential compared to other single-target AD drugs, entering a validation phase globally [1] - Adjustments were made to the sales ramp-up expectations for Dupixent due to its short-term insurance sales advantage, with revised loss forecasts for the company at 679 million, 670 million, and 282 million CNY for 2025 to 2027 [1] - Based on the promising early data for CM512, the development success rate was increased, and long-term revenue assumptions post-2027 were raised, leading to a target price adjustment from 90.89 HKD to 91.08 HKD while maintaining a "Buy" rating [1]